Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
14,731
archived clinical trials in
Psychiatric

Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Medical Research Group of Central Florida
mi
from
Orange City, FL
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Medical Research Group of Central Florida
mi
from
Orange City, FL
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Miami Research Associates
mi
from
South Miami, FL
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Miami Research Associates
mi
from
South Miami, FL
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Janus Center for Psychiatric Research
mi
from
West Palm Beach, FL
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Janus Center for Psychiatric Research
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Northwest Behavioral Research Center
mi
from
Marietta, GA
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Northwest Behavioral Research Center
mi
from
Marietta, GA
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Capstone Clinical Research
mi
from
Libertyville, IL
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Capstone Clinical Research
mi
from
Libertyville, IL
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Baber Research Group
mi
from
Naperville, IL
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Baber Research Group
mi
from
Naperville, IL
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Psychiatric Associates
mi
from
Overland Park, KA
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Psychiatric Associates
mi
from
Overland Park, KA
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Louisiana Research Associates, Inc.
mi
from
New Orleans, LA
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Louisiana Research Associates, Inc.
mi
from
New Orleans, LA
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Rochester Center for Behavioral Medicine
mi
from
Rochester Hills, MI
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Rochester Center for Behavioral Medicine
mi
from
Rochester Hills, MI
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Psychiatric Care and Research Center
mi
from
O'Fallon, MO
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Psychiatric Care and Research Center
mi
from
O'Fallon, MO
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Midwest Clinical Research Center
mi
from
Dayton, OH
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Midwest Clinical Research Center
mi
from
Dayton, OH
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Tulsa Clinical Research
mi
from
Tulsa, OK
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Tulsa Clinical Research
mi
from
Tulsa, OK
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Oregon Center for Clinical Investigations, Inc
mi
from
Salem, OR
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Oregon Center for Clinical Investigations, Inc
mi
from
Salem, OR
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Omega Medical Research
mi
from
Warwick, RI
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Omega Medical Research
mi
from
Warwick, RI
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Rainbow Research
mi
from
Barnwell, SC
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Rainbow Research
mi
from
Barnwell, SC
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Clinical Neuroscience Solution, Inc
mi
from
Memphis, TN
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Clinical Neuroscience Solution, Inc
mi
from
Memphis, TN
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
FutureSearch Trials of Dallas, LP
mi
from
Dallas, TX
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
FutureSearch Trials of Dallas, LP
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Bayou City Research, Ltd.
mi
from
Houston, TX
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Bayou City Research, Ltd.
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Red Oak Psychiatry Associates, PA
mi
from
Houston, TX
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Red Oak Psychiatry Associates, PA
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Houston Clinical Trials, LLC
mi
from
Houston, TX
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Houston Clinical Trials, LLC
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Westex Clinical Investigations
mi
from
Lubbock, TX
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Westex Clinical Investigations
mi
from
Lubbock, TX
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Research Across America
mi
from
Plano, TX
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Research Across America
mi
from
Plano, TX
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Eastside Therapeutic Resource
mi
from
Kirkland, WA
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Eastside Therapeutic Resource
mi
from
Kirkland, WA
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Midwest Research Group
mi
from
Saint Charles, MO
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Midwest Research Group
mi
from
Saint Charles, MO
Click here to add this to my saved trials
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/31/1969
Coastal Carolina Research Center
mi
from
Mount Pleasant, SC
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/31/1969
Coastal Carolina Research Center
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
STEPS: Stepped Transition in Education Program for Students With ASD
STEPS: Stepped Transition in Education Program for Students With ASD
Status: Enrolling
Updated:  12/31/1969
Virginia Polytechnic Institute and State University
mi
from
Blacksburg, VA
STEPS: Stepped Transition in Education Program for Students With ASD
STEPS: Stepped Transition in Education Program for Students With ASD
Status: Enrolling
Updated: 12/31/1969
Virginia Polytechnic Institute and State University
mi
from
Blacksburg, VA
Click here to add this to my saved trials
The Effects of Oxytocin on Startle Hyperreactivity in Patients With AUD and PTSD
The Effects of Oxytocin on Social Ability, Alcohol Approach Bias, and Startle Hyperreactivity in Veterans With Alcohol Use Disorder and Post Traumatic Stress Disorder
Status: Enrolling
Updated:  12/31/1969
San Francisco Veterans Affairs Medical Center
mi
from
San Francisco, CA
The Effects of Oxytocin on Startle Hyperreactivity in Patients With AUD and PTSD
The Effects of Oxytocin on Social Ability, Alcohol Approach Bias, and Startle Hyperreactivity in Veterans With Alcohol Use Disorder and Post Traumatic Stress Disorder
Status: Enrolling
Updated: 12/31/1969
San Francisco Veterans Affairs Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Milk Thistle in Trichotillomania in Children and Adults
Silymarin Treatment of Trichotillomania in Children and Adults: A Double-Blind, Placebo-Controlled, Cross-Over Study
Status: Enrolling
Updated:  12/31/1969
University of Chicago
mi
from
Chicago, IL
Milk Thistle in Trichotillomania in Children and Adults
Silymarin Treatment of Trichotillomania in Children and Adults: A Double-Blind, Placebo-Controlled, Cross-Over Study
Status: Enrolling
Updated: 12/31/1969
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa
Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa
Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Treatment of Severe Destructive Behavior: FCT Versus Wait-List Control
Treatment of Severe Destructive Behavior: Functional Communication Training Versus Wait-List Control
Status: Enrolling
Updated:  12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Treatment of Severe Destructive Behavior: FCT Versus Wait-List Control
Treatment of Severe Destructive Behavior: Functional Communication Training Versus Wait-List Control
Status: Enrolling
Updated: 12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
The Long-Term Treatment of Drug Addiction and Unemployment
The Long-Term Treatment of Drug Addiction and Unemployment
Status: Enrolling
Updated:  12/31/1969
The Center for Learning and Health
mi
from
Baltimore, MD
The Long-Term Treatment of Drug Addiction and Unemployment
The Long-Term Treatment of Drug Addiction and Unemployment
Status: Enrolling
Updated: 12/31/1969
The Center for Learning and Health
mi
from
Baltimore, MD
Click here to add this to my saved trials
Effects of Varenicline in Heavy Drinking Smokers
Status: Enrolling
Updated:  12/31/1969
UCLA Addictions Laboratory
mi
from
Los Angeles, CA
Effects of Varenicline in Heavy Drinking Smokers
Status: Enrolling
Updated: 12/31/1969
UCLA Addictions Laboratory
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
A Phase 3, Multicenter, Open-label Treatment-optimized, Double-blind, Randomized, Placebo-controlled, Forced-withdrawal, Parallel Group Study to Evaluate the Safety and Efficacy of Evening Dosed HLD200, a Novel Delayed and Extended Release Formulation (DELEXIS) of Methylphenidate Hydrochloride, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting
Status: Enrolling
Updated:  12/31/1969
AVIDA, Inc.
mi
from
Newport Beach, CA
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
A Phase 3, Multicenter, Open-label Treatment-optimized, Double-blind, Randomized, Placebo-controlled, Forced-withdrawal, Parallel Group Study to Evaluate the Safety and Efficacy of Evening Dosed HLD200, a Novel Delayed and Extended Release Formulation (DELEXIS) of Methylphenidate Hydrochloride, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting
Status: Enrolling
Updated: 12/31/1969
AVIDA, Inc.
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
A Phase 3, Multicenter, Open-label Treatment-optimized, Double-blind, Randomized, Placebo-controlled, Forced-withdrawal, Parallel Group Study to Evaluate the Safety and Efficacy of Evening Dosed HLD200, a Novel Delayed and Extended Release Formulation (DELEXIS) of Methylphenidate Hydrochloride, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting
Status: Enrolling
Updated:  12/31/1969
Florida Clinical Research Center, LLC
mi
from
Bradenton, FL
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
A Phase 3, Multicenter, Open-label Treatment-optimized, Double-blind, Randomized, Placebo-controlled, Forced-withdrawal, Parallel Group Study to Evaluate the Safety and Efficacy of Evening Dosed HLD200, a Novel Delayed and Extended Release Formulation (DELEXIS) of Methylphenidate Hydrochloride, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting
Status: Enrolling
Updated: 12/31/1969
Florida Clinical Research Center, LLC
mi
from
Bradenton, FL
Click here to add this to my saved trials
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
A Phase 3, Multicenter, Open-label Treatment-optimized, Double-blind, Randomized, Placebo-controlled, Forced-withdrawal, Parallel Group Study to Evaluate the Safety and Efficacy of Evening Dosed HLD200, a Novel Delayed and Extended Release Formulation (DELEXIS) of Methylphenidate Hydrochloride, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting
Status: Enrolling
Updated:  12/31/1969
Florida Clinical Research Center LLC
mi
from
Maitland, FL
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
A Phase 3, Multicenter, Open-label Treatment-optimized, Double-blind, Randomized, Placebo-controlled, Forced-withdrawal, Parallel Group Study to Evaluate the Safety and Efficacy of Evening Dosed HLD200, a Novel Delayed and Extended Release Formulation (DELEXIS) of Methylphenidate Hydrochloride, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting
Status: Enrolling
Updated: 12/31/1969
Florida Clinical Research Center LLC
mi
from
Maitland, FL
Click here to add this to my saved trials
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
A Phase 3, Multicenter, Open-label Treatment-optimized, Double-blind, Randomized, Placebo-controlled, Forced-withdrawal, Parallel Group Study to Evaluate the Safety and Efficacy of Evening Dosed HLD200, a Novel Delayed and Extended Release Formulation (DELEXIS) of Methylphenidate Hydrochloride, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting
Status: Enrolling
Updated:  12/31/1969
South Shore Psychiatric Services, PC
mi
from
Marshfield, MA
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
A Phase 3, Multicenter, Open-label Treatment-optimized, Double-blind, Randomized, Placebo-controlled, Forced-withdrawal, Parallel Group Study to Evaluate the Safety and Efficacy of Evening Dosed HLD200, a Novel Delayed and Extended Release Formulation (DELEXIS) of Methylphenidate Hydrochloride, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting
Status: Enrolling
Updated: 12/31/1969
South Shore Psychiatric Services, PC
mi
from
Marshfield, MA
Click here to add this to my saved trials
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
A Phase 3, Multicenter, Open-label Treatment-optimized, Double-blind, Randomized, Placebo-controlled, Forced-withdrawal, Parallel Group Study to Evaluate the Safety and Efficacy of Evening Dosed HLD200, a Novel Delayed and Extended Release Formulation (DELEXIS) of Methylphenidate Hydrochloride, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting
Status: Enrolling
Updated:  12/31/1969
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
A Phase 3, Multicenter, Open-label Treatment-optimized, Double-blind, Randomized, Placebo-controlled, Forced-withdrawal, Parallel Group Study to Evaluate the Safety and Efficacy of Evening Dosed HLD200, a Novel Delayed and Extended Release Formulation (DELEXIS) of Methylphenidate Hydrochloride, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting
Status: Enrolling
Updated: 12/31/1969
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
A Phase 3, Multicenter, Open-label Treatment-optimized, Double-blind, Randomized, Placebo-controlled, Forced-withdrawal, Parallel Group Study to Evaluate the Safety and Efficacy of Evening Dosed HLD200, a Novel Delayed and Extended Release Formulation (DELEXIS) of Methylphenidate Hydrochloride, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting
Status: Enrolling
Updated:  12/31/1969
Bayou City Research, Ltd.
mi
from
Houston, TX
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
A Phase 3, Multicenter, Open-label Treatment-optimized, Double-blind, Randomized, Placebo-controlled, Forced-withdrawal, Parallel Group Study to Evaluate the Safety and Efficacy of Evening Dosed HLD200, a Novel Delayed and Extended Release Formulation (DELEXIS) of Methylphenidate Hydrochloride, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting
Status: Enrolling
Updated: 12/31/1969
Bayou City Research, Ltd.
mi
from
Houston, TX
Click here to add this to my saved trials
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
A Phase 3, Multicenter, Open-label Treatment-optimized, Double-blind, Randomized, Placebo-controlled, Forced-withdrawal, Parallel Group Study to Evaluate the Safety and Efficacy of Evening Dosed HLD200, a Novel Delayed and Extended Release Formulation (DELEXIS) of Methylphenidate Hydrochloride, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting
Status: Enrolling
Updated:  12/31/1969
Westex Clinical Investigations
mi
from
Lubbock, TX
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
A Phase 3, Multicenter, Open-label Treatment-optimized, Double-blind, Randomized, Placebo-controlled, Forced-withdrawal, Parallel Group Study to Evaluate the Safety and Efficacy of Evening Dosed HLD200, a Novel Delayed and Extended Release Formulation (DELEXIS) of Methylphenidate Hydrochloride, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting
Status: Enrolling
Updated: 12/31/1969
Westex Clinical Investigations
mi
from
Lubbock, TX
Click here to add this to my saved trials
A Brief Appetite Awareness Intervention for Eating and Weight Regulation Among College Freshmen
A Brief Appetite Awareness Intervention for Eating and Weight Regulation Among College Freshmen: A Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
University of Minnesota Duluth
mi
from
Duluth, MN
A Brief Appetite Awareness Intervention for Eating and Weight Regulation Among College Freshmen
A Brief Appetite Awareness Intervention for Eating and Weight Regulation Among College Freshmen: A Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
University of Minnesota Duluth
mi
from
Duluth, MN
Click here to add this to my saved trials
Understanding Substance Use and Incident HIV/STI Among Young Black MSM
Understanding Substance Use and Incident HIV/STI Among Young Black Men Having Sex With Men (MSM)
Status: Enrolling
Updated:  12/31/1969
Grady Health System
mi
from
Atlanta, GA
Understanding Substance Use and Incident HIV/STI Among Young Black MSM
Understanding Substance Use and Incident HIV/STI Among Young Black Men Having Sex With Men (MSM)
Status: Enrolling
Updated: 12/31/1969
Grady Health System
mi
from
Atlanta, GA
Click here to add this to my saved trials
Understanding Substance Use and Incident HIV/STI Among Young Black MSM
Understanding Substance Use and Incident HIV/STI Among Young Black Men Having Sex With Men (MSM)
Status: Enrolling
Updated:  12/31/1969
Grady Infectious Diseases Clinic (Ponce Clinic)
mi
from
Atlanta, GA
Understanding Substance Use and Incident HIV/STI Among Young Black MSM
Understanding Substance Use and Incident HIV/STI Among Young Black Men Having Sex With Men (MSM)
Status: Enrolling
Updated: 12/31/1969
Grady Infectious Diseases Clinic (Ponce Clinic)
mi
from
Atlanta, GA
Click here to add this to my saved trials
Understanding Substance Use and Incident HIV/STI Among Young Black MSM
Understanding Substance Use and Incident HIV/STI Among Young Black Men Having Sex With Men (MSM)
Status: Enrolling
Updated:  12/31/1969
The Ponce de Leon Center of the Grady Health System
mi
from
Atlanta, GA
Understanding Substance Use and Incident HIV/STI Among Young Black MSM
Understanding Substance Use and Incident HIV/STI Among Young Black Men Having Sex With Men (MSM)
Status: Enrolling
Updated: 12/31/1969
The Ponce de Leon Center of the Grady Health System
mi
from
Atlanta, GA
Click here to add this to my saved trials
Understanding Substance Use and Incident HIV/STI Among Young Black MSM
Understanding Substance Use and Incident HIV/STI Among Young Black Men Having Sex With Men (MSM)
Status: Enrolling
Updated:  12/31/1969
AID Atlanta
mi
from
Atlanta, GA
Understanding Substance Use and Incident HIV/STI Among Young Black MSM
Understanding Substance Use and Incident HIV/STI Among Young Black Men Having Sex With Men (MSM)
Status: Enrolling
Updated: 12/31/1969
AID Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Understanding Substance Use and Incident HIV/STI Among Young Black MSM
Understanding Substance Use and Incident HIV/STI Among Young Black Men Having Sex With Men (MSM)
Status: Enrolling
Updated:  12/31/1969
Southside Medical Center
mi
from
Atlanta, GA
Understanding Substance Use and Incident HIV/STI Among Young Black MSM
Understanding Substance Use and Incident HIV/STI Among Young Black Men Having Sex With Men (MSM)
Status: Enrolling
Updated: 12/31/1969
Southside Medical Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Understanding Substance Use and Incident HIV/STI Among Young Black MSM
Understanding Substance Use and Incident HIV/STI Among Young Black Men Having Sex With Men (MSM)
Status: Enrolling
Updated:  12/31/1969
Rollins School of Public Health
mi
from
Atlanta, GA
Understanding Substance Use and Incident HIV/STI Among Young Black MSM
Understanding Substance Use and Incident HIV/STI Among Young Black Men Having Sex With Men (MSM)
Status: Enrolling
Updated: 12/31/1969
Rollins School of Public Health
mi
from
Atlanta, GA
Click here to add this to my saved trials
Understanding Substance Use and Incident HIV/STI Among Young Black MSM
Understanding Substance Use and Incident HIV/STI Among Young Black Men Having Sex With Men (MSM)
Status: Enrolling
Updated:  12/31/1969
SisterLove, Inc
mi
from
Atlanta, GA
Understanding Substance Use and Incident HIV/STI Among Young Black MSM
Understanding Substance Use and Incident HIV/STI Among Young Black Men Having Sex With Men (MSM)
Status: Enrolling
Updated: 12/31/1969
SisterLove, Inc
mi
from
Atlanta, GA
Click here to add this to my saved trials